FMTX - FMTX STOCK NEWS

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX) announced the election of Selwyn M. Vickers, M.D., to its board of directors. Dr. Vickers, a prominent surgeon and pancreatic cancer researcher, currently serves as senior vice president of medicine and dean at The University of Alabama at Birmingham. His expertise in healthcare disparities aligns with Forma's mission to develop drugs for rare diseases while ensuring access for diverse patient populations. He will also join the audit committee to support the company’s ongoing growth amidst its clinical development efforts.

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX) has successfully closed an underwritten public offering, issuing 6,095,000 shares of common stock at a price of $45.25 per share. This includes 795,000 shares from underwriters' exercised options, resulting in gross proceeds of approximately $275.8 million before costs. This offering, fully managed by Jefferies, SVB Leerink, and Credit Suisse, underscores the company’s commitment to advancing treatments for rare hematologic diseases and cancers.

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX) has priced an underwritten public offering of 5,300,000 shares at $45.25 each, aiming for gross proceeds of approximately $239.8 million, excluding underwriters' options. The offering is set to close around December 15, 2020. Jefferies, SVB Leerink, and Credit Suisse are managing the offering. This capital raise will support Forma's focus on developing therapies for rare hematologic diseases and cancers. All shares are being offered by the company.

Forma Therapeutics (Nasdaq: FMTX) announced a proposed public offering of 4,600,000 shares of common stock, with an option for underwriters to purchase an additional 690,000 shares. The company plans to use proceeds for various clinical developments including its lead program FT-4202 for sickle cell disease and FT-7051 for metastatic castration-resistant prostate cancer. The offering is contingent upon market conditions and a registration statement has been filed with the SEC but not yet effective.

Forma Therapeutics Holdings (Nasdaq: FMTX) reported positive results from a Phase 1 trial of FT-4202, an investigational therapy for sickle cell disease (SCD). In a cohort of nine patients, 86% of those receiving FT-4202 showed a significant increase in hemoglobin levels. Key findings included a median hemoglobin increase of 1.2 g/dL and decreases in reticulocyte counts and hemolysis markers. No serious adverse events were reported. The company is preparing for a Phase 2/3 trial to further evaluate FT-4202's efficacy in reducing SCD-related complications.

Forma Therapeutics (Nasdaq: FMTX) reported third-quarter financial results for 2020, highlighting key progress in its drug pipeline amid the COVID-19 pandemic. The company has a strong cash position of $384.3 million and has reduced R&D expenses to $24.8 million, down from $27.6 million year-over-year. Forma is set to present new data for its FT-4202 treatment for sickle cell disease at the ASH meeting in December and anticipates beginning trials for FT-7051 for advanced prostate cancer. The net loss for the quarter was $27.6 million, a decrease from $31 million in Q3 2019.

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX) has received Orphan Drug designation from the European Commission for its FT-4202 treatment targeting sickle cell disease (SCD). This designation follows a favorable opinion from the EMA's Committee for Orphan Medicinal Products. FT-4202 has previously secured multiple designations from the FDA, including Fast Track and Rare Pediatric Disease. Forma is currently conducting a Phase 1 study on FT-4202's safety and pharmacokinetics, with plans to initiate a global Phase 2/3 trial in Q1 2021.

Forma Therapeutics (Nasdaq: FMTX) has announced the acceptance of four abstracts for presentation at the 62nd American Society of Hematology (ASH) Virtual Annual Meeting, scheduled for December 5-8, 2020. Notably, an oral presentation will showcase clinical data from a Phase 1 trial of FT-4202, designed for treating sickle cell disease (SCD). The findings will provide insight into FT-4202's potential as a disease-modifying therapy. The abstracts also include mouse model research and ex-vivo patient sample analyses, reflecting the company's commitment to advancing treatment for SCD.

Forma Therapeutics Holdings (Nasdaq: FMTX) has announced its participation in three upcoming investor conferences. The events include the Credit Suisse 29th Annual Healthcare Conference from November 9-12, where they will present on November 11 at 2:45 p.m. EST; the Jefferies 2020 Virtual London Healthcare Conference from November 17-19, with a presentation on November 18 at 7:55 p.m. GMT; and the Virtual SVB Leerink Oncology 1X1 Day on November 19 for one-on-one meetings. Webcasts of the presentations will be available on their website.